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CMS Quality Indicator Initiatives Series
Part IV: Community Acquired Pneumonia
By: Lizbeth Hansen, PharmD
Pediatric Pharmacy Resident
Health care is always a top priority in this country and often the
topic of discussion and debate.
In 2004, Medicare spent $300
billion on health care costs, making it the largest purchaser of
healthcare in the nation.1
In an effort to improve the quality of health care and decrease
costs, the Department of Health
and Human Services (DHHS)
and the Centers for Medicare
and Medicaid Services (CMS)
have joined to create a program
called the Quality Initiative. The
purpose of the initiative is to encourage health care providers to
enhance the quality of care by
providing financial incentive and
to empower consumers with
quality of care information to
make more informed decisions
about their health care. The details regarding the initiatives are
described in the March issue.
(www.musc.edu/pharmacyservices/PnT/Mar07.pdf )

▪ Policies and Order Forms:
Recent P&T Committee
Approvals
▪ Formulary Updates for July,
August and September 2007

This month, the focus will be on
community acquired pneumonia.
Pneumonia is among the 10
leading causes of death in the
United States and is a significant
cause of outpatient visits and

hospitalizations.3 Although overall
hospitalization rates are declining,
hospitalizations for acute lower
respiratory tract infections have
increased steadily since 1980, particularly in the elderly.3
The 7 specific quality measures
identified by CMS are listed in
Table 1. The majority of recommendations contained within these
measures are based on the Infectious Disease Society of America
(IDSA) practice guidelines representing the best practice for the
management of community acquired pneumonia.
Data regarding performance in
these specific measures are entered into a database that is accessible to the public online through
the HHS Web site at
www.hospitalcompare.hhs.gov.
The rates of compliance with each
measure are available for MUSC,
other local hospitals, as well as
state and national averages. Data
reported for discharges from The
national benchmark and MUSC
from January through March 2007
are listed in Table 1.
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Appropriate initial antibiotic selection is critical for the treatment
of pneumonia. Guidelines for
community acquired pneumonia
(CAP) in immunocompetent patients are from the Centers for
Disease Control and Prevention
(CDC), IDSA, the Canadian Infectious Disease Society/Canadian
Thoracic Society (CIDS/CTS),
and the American Thoracic Society (ATS). All of these guidelines
reflect the following: Streptococ-

cus pneumoniae is the most
common cause of CAP; treatment that covers “atypical”
pathogens (eg, Legionella sp,
Chlamydia pneumonia, Mycoplasma pneumonia,) can be
associated with improved survival; and prevalence of antibiotic resistant S. pneumonia is
increasing. The 2 main guidelines to review include IDSA
and ATS. The links to the
guidelines are located in Table 2.

Clinical data suggests that appropriate timing of antibiotic therapy
is as critical as appropriate selection. There is increasing evidence
between timely inpatient administration of antibiotics and improved outcome among patients
with pneumonia. Kahn and colleagues found that Medicare pneumonia patients had improved survival if antibiotics were received
within 4 hours of admission.
McGarvey and colleagues found

Table 1. Quality Indicators for Community Acquired Pneumonia and Compliance Rates
MUSC Rate of Compliance
Measure

Appropriate initial
antibiotic selection
Initial antibiotic
Timing
Blood culture
performed prior
to first antibiotic
received in hospital

Pneumococcal
vaccination
Influenza
vaccination
Oxygenation
assessment
Smoking cessation
advice/counseling
30-day pneumonia
mortality

Description
Immunocompetent patients with pneumonia should
receive an initial antibiotic regimen that is consistent
with current guidelines
Pneumonia inpatients should receive within 4 hours
after arrival at the hospital
Blood cultures should be performed in the Emergency Department prior to initial antibiotic received
in the hospital
Blood cultures should be performed within 24 hours
prior to or 24 hours after hospital arrival for patients
who were transferred or admitted to the ICU within
24 hours of hospital arrival
Pneumonia inpatients age 65 and older should be
screened for pneumococcal vaccine status and administered the vaccine prior to discharge, if indicated
Pneumonia patients age 50 years and older should
be screened for influenza vaccine status and administered the vaccine prior to discharge, if indicated
Pneumonia inpatients should receive an oxygenation
assessment arterial blood gas (ABG) or pulse oximetry within 24 hours of hospital arrival
Pneumonia patients with a history of smoking
should receive smoking cessation advice or
counseling during their hospital stay
Future indicator that will be measured.

* Data are current as of March 2007

National
Benchmark

FY 2007
Year-to-Date*

97.1%

82.5%

95.6%

67%

98.9%

92.9%

99.6%

100%

97.9%

66.2%

97.4%

62.5%

100%

100%

99%

91.8%

No data currently
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that shortening the time-to-firstdose to 4 hours was associated
with improved survival. IDSA
and ATS recommend blood cultures in all patients with severe
pneumonia so that optimal therapy
can be provided. The CMS measures call for blood cultures prior
Measure

Appropriate initial
antibiotic selection

Initial antibiotic
timing

Blood cultures
in ED prior to
antibiotics
Blood cultures
within 24 hours
of arrival

to first antibiotics in the Emergency Department or within 24
hours of admission.
Vaccination in the US is suboptimal especially in high-risk patients. Protocols for pneumcoccal and influenza screening pro-

vide a means for health care providers to assess and vaccinate patients at risk. Data show that appropriate vaccination decrease the
risk for influenza-related pneumonia, pneumococcal bacteremia or
mennigitis, hospitalization, or
death. An automatic nursing order

Tools to Assist with Compliance
1. Contact or consult Infectious Disease for assistance in selection or review the following guidelines:
IDSA: www.journals.uchicago.edu/CID/journal/issues/v31n2/000441/000441.html
ATS: www.thoracic.org/sections/publications/statements/pages/mtpi/commacq1-25.html
2. Use selected clinician order forms for guidance:
Emergency Services Triage Physician Orders: www.musc.edu/cce/ORDFRMS/pdf/edtriageorders.pdf
CAP Admission Orders: www.musc.edu/cce/ORDFRMS/pdf/PUDCAP801.pdf
1. Contact or consult Infectious Disease for assistance in selection or review the guidelines
2. Review Pneumonia Severity Index Calculator: http://pda.ahrq.gov/clinic/psi/psicalc.asp
3. Use selected clinician order forms for guidance:
Emergency Services Triage Physician Orders: www.musc.edu/cce/ORDFRMS/pdf/edtriageorders.pdf
CAP Admission Orders: www.musc.edu/cce/ORDFRMS/pdf/PUDCAP801.pdf
1. Review Pneumonia Severity Index Calculator: http://pda.ahrq.gov/clinic/psi/psicalc.asp
2. Use selected clinician order forms for guidance:
Emergency Services Triage Physician Orders: www.musc.edu/cce/ORDFRMS/pdf/edtriageorders.pdf
CAP Admission Orders: www.musc.edu/cce/ORDFRMS/pdf/PUDCAP801.pdf
1. Review Pneumonia Severity Index Calculator: http://pda.ahrq.gov/clinic/psi/psicalc.asp
2. Review the IDSA and/or ATS guidelines
3. Use selected clinician order forms for guidance:
ADULT HAP/VAP/HCAP Medication Orders: www.musc.edu/cce/ORDFRMS/pdf/hapvaphcap.pdf
CAP Admission Orders: www.musc.edu/cce/ORDFRMS/pdf/PUDCAP801.pdf

Pneumococcal
vaccination

1. Automatic nursing order for all patients that meet criteria
2. Use selected clinician order forms for guidance:
Adult Immunization Orders: www.musc.edu/cce/ORDFRMS/pdf/adultimmun.pdf
Adult Pneumococcal Vaccination Standing Orders:
www.musc.edu/cce/ORDFRMS/pdf/Pneumovaxpaper.pdf

Influenza
vaccination

1. Automatic nursing order for all patients that meet criteria
2. Use selected clinician order forms for guidance:
Adult Immunization Orders: www.musc.edu/cce/ORDFRMS/pdf/adultimmun.pdf
Adult Influenza Vaccine Standing Orders: www.musc.edu/cce/ORDFRMS/pdf/Trivalentvacpaper.pdf

Smoking cessation
advice/counseling

1. Check boxes on History and Physical (H&P)
Inpatient H&P Form (checkbox on pages 6 & 7): www.musc.edu/cce/ORDFRMS/pdf/longhp.pdf
Medication Reconciliation Form: www.musc.edu/cce/ORDFRMS/pdf/medreconciliation.pdf
2. Use selected clinician order forms for guidance:
Adult Universal Admission Orders: www.musc.edu/cce/ORDFRMS/pdf/universaladmit.pdf
Discharge Orders (checkbox pg 2): www.musc.edu/cce/ORDFRMS/pdf/dischgeneral.pdf
You Can Quit (Patient Handouts):
www.musc.edu/medcenter/pted/HealthAndWellness/source/tobaccoCessation/index.htm
Family Medicine Clerkship: Smoking and Tobacco Addiction:
http://fammed.musc.edu/fmc/data/Smoking.htm
Medlineplus: Smoking Cessation Patient Information:
www.nlm.nih.gov/medlineplus/smokingcessation.html
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should be placed in each patients
chart. If the patient meets criteria,
the vaccination should be provided prior to discharge.
Inadequate oxygen in the arterial
blood is common in severe pneumonia and is a known mortality
risk factor. Giving supplemental
oxygen has been shown to decrease mortality among patients
with pneumonia. Due to the overall high compliance by all hospitals, this indicator is currently under review by the CMS advisory
board and may be retired in the
next measure update.
Lastly, tobacco use is the greatest
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cause for disease in the US.
Therefore, it is important to talk
with our patients about smoking
cessation. Hospitalization can
be an ideal opportunity for a patient to stop smoking, and smoking cessation may promote the
patient’s medical recovery. Patients who receive even brief
smoking cessation advice from
their health care providers are
more likely to quit than those
who receive no counseling whatsoever. For purposes of this
measure, a smoker is defined as
someone who has smoked cigarettes anytime during the year
prior to hospital arrival. Smoking cessation counseling must be

documented in the chart. Specific
locations are provided in Table 2.
The individual measures offer
hospitals specific goals that can be
used to improve patient care. As
part of the MUSC Excellence
campaign, the organization has
established a goal that 80% of the
CMS Indicators meet or exceed
national benchmarks. From the
data presented in Table 1, there
are a few areas that still need attention; therefore, is it critical that
every health care professional is
aware of the CMS Initiative, how
the organization is performing,
and where we need to focus our
efforts.

DID YOU KNOW...
Ceftriaxone Interaction with
Calcium-containing Products
The product labeling for ceftriaxone (Rocephin®) has been updated to include a warning regarding the co-administration of ceftriaxone and calcium-containing intravenous products. There have a
several case reports of fatal precipitate formation in neonates.
Although there are no reported
cases of ceftriaxone-calcium precipitates in patients other than
neonates, the potential for this interaction exists in patients of any
age. Generally, fatalities have
been associated with simultaneous
administration of ceftriaxone and
calcium-containing products. However, administration of
the 2 products at different times
and via different infusion lines has
also been fatal. Therefore, ceftriaxone should not be mixed with
calcium-containing products and
not administered in the same or
different infusion lines or sites in

any patient within 48 hours of
each other. Due to the potential
for this interaction, a warning
message has been placed in the
comments section of ceftriaxone
and calcium-containing products
that will be printed on the patient’s medical administration
record (MAR).
Tegaserod Available through
Treatment IND
Food and Drug Administration
(FDA) announced that it is permitting the restricted use of
tegaserod (Zelnorm®) under a
treatment investigational new
drug (IND) protocol to treat irritable bowel syndrome with constipation (IBS-C) and chronic
idiopathic constipation (CIC) in
women younger than 55 who
meet specific guidelines.
In some instances, patients with
a serious or life-threatening disease or condition who are not

enrolled in a clinical trial may be
treated with a drug not approved
by the FDA. Generally, such use
is allowed within guidelines
called a treatment IND, when no
comparable or satisfactory alternative drug or therapy is available.
In addition to the age and gender
restrictions, the IND protocol for
tegaserod limits use of the drug to
those with IBS-C or CIC whose
physicians decide the drug is
medically necessary. Patients
must sign consent materials to ensure they are fully informed of the
potential risks and benefits of
tegaserod.
Physicians that have patients with
IBS-C or CIC who meet the IND
criteria should contact the manufacturer, Novartis. More information regarding the IND can be
found at www.zelnorm.com
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POLICIES AND ORDER FORMS: RECENT P&T COMMITTEE APPROVALS
Preprinted Orders:
▪ Nutrition Support Team Standard Nutrition Orders – Standing Order Form (new)
▪ Electrolyte Replacement for Adult ICU Patients (new)
▪ Dexmedetomidine Order Form for Operating Room Patients (new)
▪ Synera™ Orders for Non-emergent Needle Sticks (new)
▪ Pediatric Sickle Cell: Acute Pain Crisis Admission Orders (new)
▪ Pediatric Sickle Cell: Acute Pain Crisis Management Orders (new)
▪ Adult Hypoglycemia Prevention and Treatment Order Form (revised)
▪ Adult Hyperglycemia Prevention and Treatment Order Form (new)
▪ Pediatric Inpatient Insulin Pump Orders (new)
▪ Pediatric Hypoglycemia Standing Orders (new)
New or Updated Policy and Procedures:
▪ Adult Hypoglycemia Prevention and Treatment Protocol (revisions to C-106)
▪ Adult Hyperglycemia Prevention and Treatment Protocol (new policy)
▪ Parenteral Nutrition and Lipid Infusions Policy (new medical center policy)
▪ Formulary Systems (revisions to C-82)
▪ Intravenous Push Administration for Adult and Pediatric Patients (new medical center policy)

FORMULARY UPDATE FOR JULY 2007
The Pharmacy and Therapeutics
Committee recently approved the
actions listed below. The formulary effective date was August 15,
2007, unless otherwise stated.
Addition:
Midodrine (ProAmantine®)
2.5-, 5-, and 10-mg tablets
Cefoxitin (Mefoxin®)
1 and 2 grams
Changes in Restriction:
1. Gadopentetate dimeglumine
(Magnevist®): The restriction has
been removed; therefore, this
agent will be available for all patients (effective July 24, 2007)
2. Gadobenate dimeglumine
(Multihance®): Gadobenate will
be available on a restricted basis
with the following restriction: for
use in patients undergoing contrast-enhanced MRI of the CNS,
hepatobiliary contrast-enhanced

imaging for metastatic detection
or a subset of MRCP (ie, evaluation of the intrahepatic biliary
tree), or patients who have endstage renal disease requiring dialysis (effective July 24, 2007)
3. Remifentanil (Ultiva®) is
now restricted to physicians on
the Anesthesiology service and
in the Emergency Department.
Line Extensions:
Sterile talc (Sclerosol®)
4-gram intrapleural aerosol
Fluticasone/salmeterol inhalers
(Advair® HFA) are now available in addition to the dry powder inhalers (Advair® Diskus).
**Please note the difference in
available strengths and dosing
between the 2 inhalers.***
Advair® HFA:
▪ 2 puffs, twice daily
▪ 45/21-, 115/21-, and 230/21microgram inhalers

Advair® Diskus:
▪ 1 inhalation, twice daily
▪ 100/50-, 250/50-, and 500/50microgram inhalers
Extemporaneous suspensions:
▪ Phenazopyridine 10 mg/mL
▪ Carvedilol 0.1 and 1.67-mg/mL
▪ Omeprazole 2-mg/mL (with
clinical justification)
▪ Dapsone 2-mg/mL
▪ Atenolol 2-mg/mL
Deletion:
Effective October 1, 2007
Insulin aspart protamine/insulin
aspart (NovoLog® 70/30) will be
deleted from the formulary due to
safety concerns. This product will
not be allowed through the nonformulary process. If the patient
is stabilized on this at home, separate orders for a basal insulin (ie,
NPH, insulin glargine) and a
rapid-acting insulin (ie, insulin
aspart) must be written.
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FORMULARY UPDATE FOR AUGUST 2007
The Pharmacy and Therapeutics
Committee recently approved the
actions listed below. The formulary effective date was September
19, 2007.
Addition:
Lidocaine/tetracaine patch
(Synera™) provides local dermal
analgesia when applied to intact
skin prior to superficial venous
access and superficial dermatological procedures. Additionally, the patch generates a mild
warming that enhances the delivery of the local anesthetics by
causing vasodilation. A preprinted
order form was approved for use
in patients at least 3 years of age.
Multiple patches should not be
used. The patch should be re-

moved prior to magnetic resonance imaging.
Topical patch: lidocaine 70
mg/tetracaine 70 mg
Line Extension:
Replacement fluid, BGK 2/0
(PrismaSOL®) is the dialysate
fluid used in conjunction with
PrismaSATE®, a replacement
fluid. These products look very
similar so please be cautious
when administering these products as they will be used concomitantly.
5-liter bag
Not Added:
Micafungin (Mycamine®)
A class review for the echinocandin anti fungal agents was

performed. This class includes
caspofungin (Cancidas®), micafungin (Mycamine®) and anidulafungin (Eraxis®). All agents have
similar efficacy against Candida
species; however, caspofungin has
additional FDA-approved indications for febrile neutropenia and
invasive aspergillosis in patients
refractory to other therapies.
Based on contract pricing, micafungin offers no substantial advantage over caspofungin and
anidulafungin is more costly than
either agent. Therefore, it was
recommended not to add micafungin to the formulary. Caspofungin will remain on the formulary as the echinocandin of choice.

FORMULARY UPDATE FOR SEPTEMBER 2007
The Pharmacy and Therapeutics
Committee recently approved the
actions listed below. The formulary effective date was October
15, 2007, unless otherwise noted.
Additions:
Fondaparinux (Arixtra®) is indicated for the prophylaxis or treatment of DVT/PE. There are limited data regarding its use in patients with a history of heparininduced thrombocytopenia. Fondaparinux is not indicated in patients with a creatinine clearance
less than 30 mL/min; therefore,
enoxaparin (Lovenox®) or unfractionated heparin should be used.
2.5-, 5-, 7,5-, and 10-mg syringes
Cocaine ophthalmic solution is
used for the diagnosis of Horners

syndrome. The 4% topical cocaine solution and sodium bicarbonate will be used to compound
the ophthalmic solution with an
appropriate pH.
(Effective November 1, 2007)
3.7% extemporaneous ophthalmic solution
Cefotetan (various)
1 and 2 grams
Line Extensions:
Mitomycin 0.02% ophthalmic
solution [0.2 mg/mL extemporaneous ophthalmic solution]
Clotrimazole (2%) 3-day vaginal
cream [21-g tube]
Albuterol HFA Inhalers
(ProAir®) [8.5-g container]

Deletions:
Sodium diatrizoate (Gastroview®)
Effective September 25, 2007
Dalteparin (Fragmin®)
[2500, 5000, 10,000 units]
Lidocaine (LMX-4®) cream
[30-g tube]
Clotrimazole(1%) 7-day vaginal
cream [45-g tube]
Esmolol (Brevibloc®)
[250-mg/mL ampules]
Digoxin (various)
[0.05- and 0.1-mg capsules]
Repository corticotrophin injection (H.P. Acthar® Gel)
[5-mL, multi-dose vial]

